Posts by author
Amalya Sargsyan
The Day Immunotherapy Went Off-Patent
In oncology, some milestones arrive with applause. Others arrive quietly. This year, one of the most important cancer drugs of the modern era begins to lose its monopoly. Nivolumab, one of the first PD-1 inhibitors to reach patients, is set…
Fedro Peccatori Between Science and the Human Heart
When I first connected with Professor Fedro Peccatori, the line between us was anything but fixed: he was calling from a moving train between Padova to Milan, between obligations. Yet the instability of the connection seemed fitting. His entire career…
The Life Journey of Giuseppe Curigliano: From Becoming an Expert to Making Experts
From Rome to Milan to ESMO’s presidency — a story of science, courage, and mentorship. I am in Yerevan. Giuseppe Curigliano is in Milan, just back from Asia. “JSMO, CSCO, Korea, Japan, China…” he sighs, then laughs. “Too much travel?”…
Curious, Rejected,Accepted: An ESO Fellow’s Road to Becoming an Oncologist
It was 2018, and I was a fifth-year medical student at Yerevan State Medical University. Word spread that our new oncology professor was someone extraordinary: Gevorg Tamamyan - a Harvard-trained, Nature-published pioneer of pediatric oncology in Armenia and president of…
Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
It is often said in medicine that the only true constant in facing life-threatening diseases is change. Nowhere is this more evident than in oncology, where advances in chemotherapy, targeted therapies, immunotherapies, and other novel agents continue to spark hope.…